Neosynephrin-Pos (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Neosynephrin-Pos, is a Alpha‑adrenergic agonist presented as an ophthalmic preparation for ocular use. It is employed to dilate the pupil for diagnostic examinations and to reduce conjunctival redness in a variety of patients.

GNH USA supplies Neosynephrin-Pos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neosynephrin-Pos is an ocular alpha‑adrenergic agonist used in conditions affecting the anterior segment of the eye. - Diagnostic mydriasis: provides rapid pupil dilation to facilitate fundus and retinal examinations. - Conjunctival hyperemia: reduces ocular redness by vasoconstricting superficial vessels. - Pre‑operative ocular preparation: creates a dilated pupil for intra‑ocular surgeries and laser procedures.

Adverse reactions are generally mild and transient, but serious events can occur in susceptible individuals.

Common Side Effects: - Burning or stinging sensation in the eye - Temporary blurred vision - Mild headache - Eye irritation or itching - Transient increase in intra‑ocular pressure - Mild facial flushing

Serious or Rare Side Effects: - Acute angle‑closure glaucoma - Severe allergic reaction (anaphylaxis) - Persistent mydriasis lasting several hours - Significant ocular hypertension - Systemic hypertension or tachycardia - Cardiac arrhythmia

Neosynephrin-Pos should be used with awareness of specific safety considerations. - Contraindicated in narrow‑angle glaucoma: risk of precipitating angle‑closure. - Use caution in patients with uncontrolled systemic hypertension: may raise blood pressure. - Avoid in individuals with known hypersensitivity to phenylephrine or any excipients. - Do not exceed recommended frequency: prolonged use can lead to rebound redness. - Store at room temperature: keep in the original container, protect from moisture and direct light.

Phenylephrine may interact with other agents that affect adrenergic tone or blood pressure.

Major Interactions (Avoid): - Systemic sympathomimetics (e.g., pseudoephedrine): additive hypertensive effect. - Monoamine oxidase inhibitors (MAOIs): risk of excessive vasoconstriction.

Moderate Interactions (Monitor Closely):\n- Antihypertensive medications: possible reduction of blood‑pressure‑lowering effect. - Tricyclic antidepressants: may enhance cardiovascular stimulation. - Other ocular vasoconstrictors (e.g., naphazoline): increased risk of ocular hypertension.